Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Core Laboratories (CLB) 10K Form and Latest SEC Filings 2026

Core Laboratories logo
$13.72 +0.16 (+1.14%)
Closing price 05/19/2026 03:59 PM Eastern
Extended Trading
$13.72 +0.01 (+0.04%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Core Laboratories SEC Filings & Recent Activity

Core Laboratories (NYSE:CLB) has submitted 120+ documents to the U.S. Securities and Exchange Commission (SEC) since 2023. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SD submitted on May 15, 2026.

Form 4
Core Laboratories Inc. /DE/ Reports Ownership Change on Apr. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Core Laboratories Files Current Report on May. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Core Laboratories Files Annual Report on Mar. 20, 2026

The 10-K contains Core Laboratories's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Core Laboratories SEC Filing History

Browse Core Laboratories' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 1:49 PM
Core Laboratories (1958086) Filer
Form SD
Specialized Disclosure Report  
05/13/2026 3:54 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 3:43 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2026 11:22 AM
Core Laboratories (1958086) Issuer
Murray Katherine (1930744) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 6:43 PM
Core Laboratories (1958086) Issuer
MARTINOVICH ROBERT F (1251674) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 6:45 PM
Core Laboratories (1958086) Issuer
Temeng Kwaku (1846675) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 6:46 PM
Core Laboratories (1958086) Issuer
Klingensmith Harvey Robert (1800107) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 6:47 PM
ANASTASIO CURT (1032097) Reporting
Core Laboratories (1958086) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 6:41 PM
Carnes Martha Z. (1678397) Reporting
Core Laboratories (1958086) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 4:21 PM
Core Laboratories (1958086) Filer
Form DEF 14A
03/31/2026 4:22 PM
Core Laboratories (1958086) Filer
Form DEFA14A
03/31/2026 4:23 PM
Core Laboratories (1958086) Filer
Form ARS
03/26/2026 4:39 PM
Core Laboratories (1958086) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/23/2026 3:59 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2026 8:54 PM
Core Laboratories (1958086) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/17/2026 5:15 AM
Core Laboratories (1958086) Filer
Form 8-K/A
03/05/2026 3:11 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 10:00 AM
Core Laboratories (1958086) Issuer
Teo Sow Hang (2017091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 10:02 AM
Bruno Lawrence (1730336) Reporting
Core Laboratories (1958086) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 10:04 AM
Core Laboratories (1958086) Issuer
Hill Christopher Scott (1641315) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 10:06 AM
Core Laboratories (1958086) Issuer
Gresham Gwendolyn (1842114) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 10:07 AM
Core Laboratories (1958086) Issuer
Tattoli Mark Damian (1872069) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2026 3:19 PM
Core Laboratories (1958086) Subject
EARNEST PARTNERS LLC (1102578) Filed by
Form SCHEDULE 13G/A
02/04/2026 3:58 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 2:16 PM
Bruno Lawrence (1730336) Reporting
Core Laboratories (1958086) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 2:17 PM
Core Laboratories (1958086) Issuer
Hill Christopher Scott (1641315) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 2:18 PM
Core Laboratories (1958086) Issuer
Gresham Gwendolyn (1842114) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 2:18 PM
Core Laboratories (1958086) Issuer
Tattoli Mark Damian (1872069) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 6:35 PM
Core Laboratories (1958086) Issuer
Teo Sow Hang (2017091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 10:18 AM
ARIEL INVESTMENTS, LLC (936753) Filed by
Core Laboratories (1958086) Subject
Form SCHEDULE 13G/A
10/30/2025 1:56 PM
Core Laboratories (1958086) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
10/23/2025 3:05 PM
Core Laboratories (1958086) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/22/2025 3:15 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2025 4:15 PM
Core Laboratories (1958086) Issuer
Teo Sow Hang (2017091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 4:16 PM
Core Laboratories (1958086) Issuer
Tattoli Mark Damian (1872069) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 4:27 PM
Core Laboratories (1958086) Subject
DISCIPLINED GROWTH INVESTORS INC /MN (1050442) Filed by
Form SCHEDULE 13G/A
08/05/2025 8:17 AM
Core Laboratories (1958086) Issuer
Teo Sow Hang (2017091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2025 8:21 AM
Core Laboratories (1958086) Issuer
Tattoli Mark Damian (1872069) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 10:22 AM
Core Laboratories (1958086) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
06/27/2025 11:59 AM
Core Laboratories (1958086) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
06/05/2025 4:18 PM
ARIEL INVESTMENTS, LLC (936753) Filed by
Core Laboratories (1958086) Subject
Form SCHEDULE 13G/A
Trump's gold order: the announcement they won't put on the front page (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
05/27/2025 3:27 PM
Core Laboratories (1958086) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Core Laboratories SEC Filings - Frequently Asked Questions

Core Laboratories (CLB) has submitted 120+ filings to the SEC since 2023. You can browse the complete history or filter by form type using the tools above.

Core Laboratories's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SD submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:CLB) was last updated on 5/20/2026 by MarketBeat.com Staff.
From Our Partners